Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

Robert F. Kennedy Jr. struggled Wednesday to answer questions about Medicare and Medicaid or to provide details about how he ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

High vaccine wastage and low vaccination and booster rates marred the government’s P74.68-million COVID-19 National ...

Andy predicts the rise in trends such as predictive analytics to predict waves such as the next pandemic or even individual health related diseases or illnesses.

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...